Literature DB >> 24590655

Nivolumab: promising survival signal coupled with limited toxicity raises expectations.

Geraldine O'Sullivan Coyne1, Ravi A Madan, James L Gulley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24590655      PMCID： PMC6624830          DOI： 10.1200/JCO.2013.54.5996

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  20 in total

1.  An update on current management of advanced renal cell cancer, biomarkers, and future directions.

Authors:  Wanqing Iris Zhi; Jenny J Kim
Journal:  Ann Cancer Res       Date:  2014

Review 2.  Nivolumab: a review of its use in patients with malignant melanoma.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

Review 3.  Classifying Cancers Based on T-cell Infiltration and PD-L1.

Authors:  Michele W L Teng; Shin Foong Ngiow; Antoni Ribas; Mark J Smyth
Journal:  Cancer Res       Date:  2015-06-01       Impact factor: 12.701

Review 4.  Immunotherapy of Prostate Cancer: Facts and Hopes.

Authors:  Marijo Bilusic; Ravi A Madan; James L Gulley
Journal:  Clin Cancer Res       Date:  2017-06-29       Impact factor: 12.531

Review 5.  Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.

Authors:  Lisa A Kottschade
Journal:  Curr Oncol Rep       Date:  2018-03-06       Impact factor: 5.075

6.  Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.

Authors:  K V Woan; M Lienlaf; P Perez-Villaroel; C Lee; F Cheng; T Knox; D M Woods; K Barrios; J Powers; E Sahakian; H W Wang; J Canales; D Marante; K S M Smalley; J Bergman; E Seto; A Kozikowski; J Pinilla-Ibarz; A Sarnaik; E Celis; J Weber; E M Sotomayor; A Villagra
Journal:  Mol Oncol       Date:  2015-04-24       Impact factor: 6.603

Review 7.  Adding fuel to the fire: immunogenic intensification.

Authors:  Geraldine O'Sullivan Coyne; James L Gulley
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 8.  Harnessing the immune system to improve cancer therapy.

Authors:  Nikos E Papaioannou; Ourania V Beniata; Panagiotis Vitsos; Ourania Tsitsilonis; Pinelopi Samara
Journal:  Ann Transl Med       Date:  2016-07

Review 9.  Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.

Authors:  Zhong-Yi Dong; Si-Pei Wu; Ri-Qiang Liao; Shu-Mei Huang; Yi-Long Wu
Journal:  Tumour Biol       Date:  2016-01-16

10.  Urgent Need to Define Pretreatment Predictors of Immune Check Point Inhibitors Related Endocrinopathies: A Case Report and Review of Literature.

Authors:  Vishal Sehgal; Richard Childress
Journal:  J Transl Int Med       Date:  2017-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.